| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000043598 |
| Receipt No. | R000049782 |
| Scientific Title | Exploratory study of anti-aging effects of supplement intake |
| Date of disclosure of the study information | 2021/03/12 |
| Last modified on | 2021/09/10 (Ver. 3) |
| Basic information | ||
| Public title | Exploratory study of anti-aging effects of supplement intake | |
| Acronym | Study of anti-aging effects | |
| Scientific Title | Exploratory study of anti-aging effects of supplement intake | |
| Scientific Title:Acronym | Study of anti-aging effects | |
| Region |
|
|
| Condition | ||
| Condition | Healthy Adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Exploratory evaluation of the anti-aging effect of supplements taken continuously for 4 weeks. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Mitochondrial number (mtDNA / gDNA), sirt1 gene expression level (sirt1 mRNA / GAPDH mRNA) |
| Key secondary outcomes | Urinary 8-OHdG, urinary pentosidine, blood fatty acid fraction, blood e-NAMPT, saliva Sirt2, intestinal flora, oral flora
Options *: Age-related gene/protein expression levels (melatonin, GH/IGF-1, polyamine, DHEA-S, BDNF, etc.), telomere length, hexanoyl lysine (HEL), isolastan, CoQ10 oxidation rate, peroxidation Lipid (LPO), total antioxidant capacity (STAS, PAO), T cell count, T cell proliferation coefficient, CD4/CD8 T cell ratio, naive T cell count, naive/memory T cell ratio, B cell count, NK cell count, CD8 + CD28 + T cell count, methylated DNA, vitamin C, folic acid, rutin, zeaxanthin, beta-cryptoxanthin, lycopene, alpha-carotene, beta-carotene, vitamin A, tocopherol, ubiquinol, cortisol, luteinizing hormone, follicle Stimulant hormone, oxidatively denatured LDL (LAB), soluble LOX-1 *: Optional evaluation items will be judged from the measurement results of the default primary evaluation items and secondary evaluation items, and will be implemented as necessary. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 2 | ||
| Purpose of intervention | Prevention | ||
| Type of intervention |
|
||
| Interventions/Control_1 | Group I: Take 2 capsules of test food A * continuously for 4 weeks around 10 am (on an empty stomach between meals).
*Test food A is either NMN-containing supplement or placebo. |
||
| Interventions/Control_2 | Group I: Take 2 capsules of test food B * continuously for 4 weeks around 10 am (on an empty stomach between meals).
*Test food B is either NMN-containing supplement or placebo. |
||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document
2.Men and women aged 45 to 64 at the time of consent |
|||
| Key exclusion criteria | 1.Persons who have chronic illness, receiving medication, have a serious disease history
2.Persons who are allergic to the test food 3.Persons who are breast-feeding, pregnant, or who plan or wish to become pregnant during the study period. 4.Persons who regularly use medicines, foods for specified health use, and health foods etc. that may affect aging, such as drugs with antioxidant activity 5.Persons who have participated in other tests within the first month before the start of the test, or those who intend to participate in another exam after consenting to this exam 6.Persons who were judged as inappropriate for subjects by the principal investigator |
|||
| Target sample size | 60 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Healthcare Systems Co., Ltd. | ||||||
| Division name | Research and Development Department | ||||||
| Zip code | 105-0004 | ||||||
| Address | Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN | ||||||
| TEL | 03-6809-2722 | ||||||
| masudat@hc-sys.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Healthcare Systems Co., Ltd. | ||||||
| Division name | Research and Development Department | ||||||
| Zip code | 105-0004 | ||||||
| Address | Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN | ||||||
| TEL | 03-6809-2722 | ||||||
| Homepage URL | |||||||
| masudat@hc-sys.jp | |||||||
| Sponsor | |
| Institute | Healthcare Systems Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | MIRAILAB BIOSCIENCE Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The Ethics Committee of Healthcare Systems Co., Ltd. |
| Address | Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN |
| Tel | 03-6809-2722 |
| soumu@hc-sys.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 60 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049782 |